1/6
07:00 am
tnxp
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
Low
Report
Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026
1/3
01:08 am
tnxp
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
Medium
Report
Tonix Pharmaceuticals (NASDAQ:TNXP) was downgraded by analysts at
Wall S
12/30
08:12 am
tnxp
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
Medium
Report
Tonix prices 615,025 shares at $16.26 in registered direct offering [Yahoo! Finance]
12/29
08:12 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering [Yahoo! Finance]
12/29
08:01 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) [Yahoo! Finance]
12/29
07:57 am
tnxp
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
Medium
Report
Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering
12/29
07:45 am
tnxp
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
Medium
Report
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)
12/16
07:51 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University [Yahoo! Finance]
12/16
07:00 am
tnxp
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
Low
Report
Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University
12/9
07:00 am
tnxp
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
Low
Report
Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel
11/24
07:00 am
tnxp
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
Medium
Report
Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder
11/17
07:22 am
tnxp
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment [Yahoo! Finance]
11/17
07:00 am
tnxp
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
Medium
Report
Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment
11/14
09:42 am
tnxp
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook [Seeking Alpha]
Low
Report
Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook [Seeking Alpha]
11/12
05:43 am
tnxp
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News [Yahoo! Finance]
Low
Report
Several Insiders Invested In Tonix Pharmaceuticals Holding Flagging Positive News [Yahoo! Finance]
11/10
04:32 pm
tnxp
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
Medium
Report
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights [Yahoo! Finance]
11/10
04:15 pm
tnxp
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
Low
Report
Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights
11/6
07:00 am
tnxp
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
Medium
Report
Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference
11/4
07:00 am
tnxp
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
Medium
Report
Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection
10/28
07:00 am
tnxp
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
Medium
Report
Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025
10/27
07:00 am
tnxp
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
Medium
Report
Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence
10/22
07:00 am
tnxp
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
Low
Report
Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital
10/21
07:00 am
tnxp
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
Low
Report
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence
10/17
07:00 am
tnxp
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025
Low
Report
Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025